Retrospective evaluation of L76V-positive pts. with virological failure and complete genotypic data (N=47)

Follow-up therapy:
- **ATV or SQV + OBT** (N=10)
  - Loss of follow-up (N=4)
    - Patients week 96 with VL>50 cop/mL (N=5)
    - Patients week 96 with VL<50 cop/mL (N=1)
      - 2nd resistance test (N=4)

Follow-up therapy:
- **ATV or SQV + LPV or APV + OBT** (N=18)
  - Loss of follow-up (N=6)
    - Patients week 96 with VL>50 cop/mL (N=4)
    - Patients week 96 with VL<50 cop/mL (N=8)
      - 2nd resistance test (N=4)

Follow-up therapy:
- **LPV or APV + OBT** (N=19)
  - Loss of follow-up (N=14)
    - Patients week 96 with VL>50 cop/mL (N=5)
    - Patients week 96 with VL<50 cop/mL (N=0)
      - 2nd resistance test (N=2)